注射用奥沙利铂致全身肌肉疼痛1例分析  

One case of generalized myalgia caused by oxaliplatin

作　　者：方美琳 郑慧敏 王存泽 王凌[1,2] 阮君山 FANG Meilin;ZHENG Huimin;WANG Cunze;WANG Ling;RUAN Junshan(Department of Pharmacy,Fujian Provincial Clinical Medical College of Fujian Medical University,Fujian Provincial Hospital,Fuzhou Fujian 350001,China;School of Pharmacy,Fujian Medical University,Fuzhou Fujian 350004,China)

机构地区：[1]福建医科大学省立临床医学院,福建省立医院,福建福州350001 [2]福建医科大学药学院,福建福州350004

出　　处：《中国药物警戒》2024年第2期208-210,共3页Chinese Journal of Pharmacovigilance

基　　金：福建省卫生健康中青年骨干人才培养项目(2022GGA001)。

摘　　要：目的 研究注射用奥沙利铂在胃癌患者治疗中的安全性。方法 对1例51岁男性患者因恶性肿瘤术后化疗给予奥沙利铂治疗出现全身肌肉疼痛诊疗过程进行回顾性分析。结果 实验室检查:糖类抗原CA19-9 6.09 U·mL^(-1),CA72-4 2.61 U·mL^(-1),CA15-3 6.99 U·mL^(-1),癌胚抗原2.45 ng·mL^(-1),甲胎蛋白1.76 ng·mL^(-1),肌酸激酶CK49 U·L^(-1),血清肌酐83μmol·L^(-1),经实验室检查与辅助检查排除其他原因导致的全身肌肉疼痛,考虑为奥沙利铂引起的不良反应。停用奥沙利铂后,次日患者诉肌肉疼痛减轻,VAS评分7分。停药1周后患者肌肉疼痛消失,VAS评分0分。结论注射用奥沙利铂可能会增加全身肌肉疼痛不良反应发生的风险,临床需警惕。Objective To study the safety of oxaliplatin for injection in patients with gastric cancer.Methods The process of treating one 51-year-old male patient who developed generalised myalgia as a result of postoperative chemotherapy for a malignant tumor after being given oxaliplatin was analyzed.Results The laboratory test tests were as follows:the level of carbohydrate antigen was 19-9(CA19-9)6.09 U·mL^(-1),CA72-4 was 2.6 U·mL^(-1),CA15-3 was 6.99 U·mL^(-1),carcinoembryonic antigen was 2.45 ng·mL^(-1),alpha fetoprotein was 1.76 ng·mL^(-1),creatine kinase(CK)was 49 U·L^(-1),and serum creatinine(SCr)was 83μmoL·L-1.After other causes of generalized myalgia were ruled out,the possibility of adverse reactions being caused by oxaliplatin was taken into account.Upon discontinuation of oxaliplatin,the patient reported reduced muscle soreness,with a VAS score of 7.One week later,the patient’s muscle soreness completely disappeared,resulting in a VAS score of 0.Conclusion Oxaliplatin for injection may increase the risk of generalised muscle pain,so clinical vigilance is required.

关 键 词：奥沙利铂 注射 肌肉疼痛 药品不良反应 胃癌 化疗 肿瘤 

分 类 号：R979.1[医药卫生—药品] R994.11[医药卫生—药学]